Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Cancer cases in India estimated to reach 1.57 million in 2025
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated